Umbilical cord-derived mesenchymal stem cells

1. Umbilical cord-derived mesenchymal stem cells have no effect on adverse event incidence in humans.

   “There was no difference of incidence of AEs between the two groups.”

   Human trialpatients with aging frailty; compared with placebo6 months

   Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study

   Stem cell research & therapy·29 Apr 2024

1. Umbilical cord-derived mesenchymal stem cells decrease TNF-α and IL-17 in humans.

   “Inflammatory cytokines (TNF-α, IL-17) exhibited declines in MSCs group at 6 months compared to the placebo group (p = 0.034 and 0.033, respectively).”

   Human trialpatients with aging frailty; compared with placebo6 months

   Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study

   Stem cell research & therapy·29 Apr 2024

More on TNF-α and IL-17

1. Umbilical cord-derived mesenchymal stem cells increase grip strength in humans.

   “The measurement of grip strength revealed group difference with MSCs group demonstrating better performance, particularly at 6 months (p = 0.002).”

   Human trialpatients with aging frailty; compared with placebo6 months

   Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study

   Stem cell research & therapy·29 Apr 2024

1. Umbilical cord-derived mesenchymal stem cells improve timed Up and Go performance in humans.

   “The timed up and go (TUG) physical performance test revealed significant group difference and showed continual enhancements over 6 months (p < 0.05).”

   Human trialpatients with aging frailty; compared with placebo6 months

   Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study

   Stem cell research & therapy·29 Apr 2024

1. Umbilical cord-derived mesenchymal stem cells increase EQ-VAS score in humans.

   “EQ-VAS scores of MSCs group improved significantly at 2 month (p = 0.023) and continued until the end of the 6-month visit”

   Human trialpatients with aging frailty; compared with placebo2–6 months

   Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study

   Stem cell research & therapy·29 Apr 2024

1. Umbilical cord-derived mesenchymal stem cells increase SF-36 physical component score in humans.

   “significant improvements in PCS of SF-36 were observed from first post-treatment visit and sustained throughout the follow-up period, with greater changes compared to the placebo group (p = 0.042).”

   Human trialpatients with aging frailty; compared with placebo6 months

   Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study

   Stem cell research & therapy·29 Apr 2024